Replies to post #35867 on Biotech Values

[DewDiligence]

3Q06 Baraclude sales were $22M, +57% from 2Q06 due to rollout and a partial quarter of sales in the UK, France, Germany, and Japan.

Baraclude still lags Hepsera (3Q06 sales: $55M), but there’s little doubt that it is the main competitor for Tyzeka in the HBV market.